A multicenter phase II randomized trial to evaluate systemic therapy versus systemic therapy in combination with stereotactic radiotherapy in patients with metastatic colorectal cancer

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 105

Inclusion Criteria

- Histological proof of colorectal carcinoma (CRC)
- Colorectal metastatic disease
- Ten or less metastases as determined by the UCMU central review
- Stable disease or partial response after induction chemotherapy according to
RECIST 1.1 criteria
- Written informed consent
For all in- and exclusion criteria we want to refer to chapter 4 of the
protocol.

Exclusion Criteria

- Possible treatment with curative intent according to local tumor board
- Substantial overlap with a previously treated radiation volume. Previous
radiotherapy is allowed as long as the composite plan meets dose constraints
herein.
- Contra-indication MR-LINAC (pacemaker or implantable
cardioverter-defibrillator)
For all in- and exclusion criteria we want to refer to chapter 4 of the
protocol.

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method

Secondary Outcome Measures

Name	Time	Method

Related Trials

A multicenter randomized phase II trial evaluating the efficacy and safety of intrapericardial left superior pulmonary vein ligation or division for prevention of thrombosis in the stump

RecruitingPhase 2

iigata Chest Surgery Study Group

Updated 10/17/2023

A multicenter randomized phase II Trial assessing the activity of Gemcitabine - Oxaliplatin chemotherapy alone or in combination with Cetuximab in patients with advanced biliary cancer - BINGO

Medizinische Hochschule Hannover

Updated 3/19/2012

A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML. - AML-AZA

Phase 1

niversitaetsklinikum Muenster

Updated 9/9/2024

A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients aged >= 66 years. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT-older AML/high-risk MDS patients

Phase 2

HOVO

Updated 4/23/2024

A randomized study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy. ,

Phase 1

HOVON Foundation

Updated 8/2/2021

A randomized phase II multicenter study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine in UNFIT (i.e. HCT-CI >= 3) adult AML and high risk myelodysplasia (MDS) (IPSS-R > 4.5) patients. A study in the frame of the masterprotocol of parallel randomized phase II studies in UNFIT- AML/high-risk MDS patients.

CompletedPhase 2

HOVO

Updated 8/19/2024

A randomized study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy, aged >= 66 years.

Phase 1

HOVON Foundation

Updated 8/8/2016

A randomized study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy, aged >= 66 years.

Phase 1

HOVON Foundation

Updated 5/8/2017

A randomized study to assess the tolerability and efficacy of the addition ofibrutinib to 10-day decitabine treatment in patients with AML and high riskmyelodysplasia (MDS), UNFIT for intensive chemotherapy, aged >= 66years.

Phase 1

HOVON Foundation

Updated 8/21/2017

Clinical Trial to study the effect of the treatment with eribulin and endocrine therapy in metastatic breast cancer patients

Phase 1

Medica Scientia Innovation Research (MEDSIR)

Updated 2/28/2019

A multicenter phase II randomized trial to evaluate systemic therapy versus systemic therapy in combination with stereotactic radiotherapy in patients with metastatic colorectal cancer

Recruitment & Eligibility

Study & Design

Related Trials

A multicenter randomized phase II trial evaluating the efficacy and safety of intrapericardial left superior pulmonary vein ligation or division for prevention of thrombosis in the stump

A multicenter randomized phase II Trial assessing the activity of Gemcitabine - Oxaliplatin chemotherapy alone or in combination with Cetuximab in patients with advanced biliary cancer - BINGO

A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML. - AML-AZA

A randomized study to assess the tolerability and efficacy of the addition of midostaurin to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy. ,

A randomized study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy, aged >= 66 years.

A randomized study to assess the tolerability and efficacy of the addition of ibrutinib to 10-day decitabine treatment in patients with AML and high risk myelodysplasia (MDS), UNFIT for intensive chemotherapy, aged >= 66 years.

A randomized study to assess the tolerability and efficacy of the addition ofibrutinib to 10-day decitabine treatment in patients with AML and high riskmyelodysplasia (MDS), UNFIT for intensive chemotherapy, aged >= 66years.

Clinical Trial to study the effect of the treatment with eribulin and endocrine therapy in metastatic breast cancer patients

Clinical Trial Alerts

Clinical Trial Alerts